These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20568781)

  • 21. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
    Thomas JB; Mascarella SW; Rothman RB; Partilla JS; Xu H; McCullough KB; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 May; 41(11):1980-90. PubMed ID: 9599247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress.
    Matsuzawa S; Suzuki T; Misawa M; Nagase H
    Eur J Pharmacol; 1999 Feb; 368(1):9-16. PubMed ID: 10096764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.
    Carroll FI; Chaudhari S; Thomas JB; Mascarella SW; Gigstad KM; Deschamps J; Navarro HA
    J Med Chem; 2005 Dec; 48(26):8182-93. PubMed ID: 16366600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
    Hiebel AC; Lee YS; Bilsky E; Giuvelis D; Deschamps JR; Parrish DA; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Partilla JS; Rothman RB; Cheng K; Jacobson AE; Rice KC
    J Med Chem; 2007 Aug; 50(16):3765-76. PubMed ID: 17625813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors.
    Zimmerman DM; Leander JD; Cantrell BE; Reel JK; Snoddy J; Mendelsohn LG; Johnson BG; Mitch CH
    J Med Chem; 1993 Oct; 36(20):2833-41. PubMed ID: 8410998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
    Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison with naloxone of two dynorphin A analogues with K- and delta-opioid antagonist activity.
    Capasso A
    Med Chem; 2009 Jan; 5(1):1-6. PubMed ID: 19149644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
    Solinas M; Goldberg SR
    Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
    Le Bourdonnec B; Barker WM; Belanger S; Wiant DD; Conway-James NC; Cassel JA; O'Neill TJ; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2006-12. PubMed ID: 18313920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; Herbertz T; Yap GP; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7278-89. PubMed ID: 17149858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).
    Kormos CM; Ondachi PW; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
    J Med Chem; 2018 Sep; 61(17):7546-7559. PubMed ID: 30032602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists.
    Carroll FI; Melvin MS; Nuckols MC; Mascarella SW; Navarro HA; Thomas JB
    J Med Chem; 2006 Mar; 49(5):1781-91. PubMed ID: 16509593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).
    Ondachi PW; Kormos CM; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
    J Med Chem; 2018 Sep; 61(17):7525-7545. PubMed ID: 30117738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model.
    Carroll FI; Harris LS; Aceto MD
    Eur J Pharmacol; 2005 Nov; 524(1-3):89-94. PubMed ID: 16236279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.
    Grundt P; Williams IA; Lewis JW; Husbands SM
    J Med Chem; 2004 Oct; 47(21):5069-75. PubMed ID: 15456250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)- 3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies.
    Soukara S; Maier CA; Predoiu U; Ehret A; Jackisch R; Wünsch B
    J Med Chem; 2001 Aug; 44(17):2814-26. PubMed ID: 11495592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and localization of delta-, kappa-, and mu-opioid receptors in human spermatozoa and implications for sperm motility.
    Agirregoitia E; Valdivia A; Carracedo A; Casis L; Gil J; Subiran N; Ochoa C; Irazusta J
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4969-75. PubMed ID: 16984994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.